版本:
中国

BRIEF-Protalix Biotherapeutics announces positive results from phase II clinical trial of Alidornase Alfa

April 12 Protalix Biotherapeutics Inc

* Protalix Biotherapeutics announces positive results from phase II clinical trial of Alidornase Alfa (air dnase) for the treatment of cystic fibrosis

* Protalix Biotherapeutics Inc - sixteen patients were enrolled in study, all of whom completed study

* Protalix Biotherapeutics Inc - Alidornase Alfa was well tolerated with no serious adverse events reported

* Protalix Biotherapeutics - adverse events that occurred during study were mild and transient in nature for phase ii clinical trial of Alidornase Alfa

* Protalix Biotherapeutics - in vitro study of air dnase showed significant inhibition of pseudomonas aeruginosa Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐